SD-OCT measurements of RNFL thickness may help predict likelihood of glaucoma diagnosis

Article

Researchers have developed a methodology for calculating likelihood ratios for glaucoma diagnosis using continuous retinal nerve fiber layer (RNFL) thickness measurements taken with spectral-domain optical coherence tomography (SD-OCT), and found that average RNFL thickness values < 86 ?m were associated with negative likelihood ratios of such a diagnosis.

La Jolla, CA-Researchers have developed a methodology for calculating likelihood ratios for glaucoma diagnosis using continuous retinal nerve fiber layer (RNFL) thickness measurements taken with spectral-domain optical coherence tomography (SD-OCT), and found that average RNFL thickness values

For this observational cohort study, researchers from the Hamilton Glaucoma Center at the University of California, San Diego, recruited a total of 187 patients (262 eyes) with glaucoma and 100 controls (190 eyes) from the Diagnostic Innovations Glaucoma Study. In the glaucoma group, eyes with preperimetric and perimetric glaucomatous damage were included, while the control group was comprised of healthy eyes with normal visual fields in subjects recruited from the general population.

All eyes underwent RNFL imaging with SD-OCT. Using a methodology based on estimating the tangents to the receiver operating characteristic (ROC) curve, researchers estimated the likelihood ratios for a diagnosis of glaucoma for specific global RNFL thickness measurements.

Likelihood ratios were possible for continuous values of average RNFL thickness, and average RNFL thickness values

The abstract can be accessed: here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.